Looking to learn more about Regulus and our work in #ADPKD? Our team will be at conferences with Evercore and Piper Sandler in December presenting and hosting meetings. We hope to see you there! #nephrology
关于我们
Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a maturing microMarkersSM biomarkers platform and a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is located in San Diego, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.
- 网站
-
https://www.regulusrx.com
Regulus Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Diego，CA
- 类型
- 上市公司
- 创立
- 2007
- 领域
- microRNA和great company culture
地点
-
主要
获取路线
US，CA，San Diego，92121
Regulus Therapeutics员工
动态
-
Today we announced our third quarter financial results and recent updates. Read more: https://lnkd.in/ewfYUSVq $RGLS
-
-
We’re excited to announced that our late breaking poster on RGLS8429 in #ADPKD was accepted at American Society of Nephrology's #KidneyWk meeting! The poster, entitled “RGLS8429 increases urinary PC1 and PC2 and reduces height-adjusted total kidney volume (htTKV) in a Phase 2a multiple ascending dose (MAD) study in patients with ADPKD” will be available for viewing on October 24th at 10 a.m. PT during the Late-breaking Science Posters session. Additionally, if you’ll be at #KidneyWk for the Early Programs check out Ed Lee, VP, Translational Biology’s presentation, “miRNA Therapeutics for Polycystic Kidney Disease” during the “Advances in Research Conference - Genome Engineering and RNA-Based Therapeutics: From Bench to Potentially Curative Medicines” session October 23rd at 3:30 p.m. PT. We look forward to seeing you there!
-
-
We are very excited that the 2024 Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. Our work developing novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets follows on from this key discovery.
BREAKING NEWS The Nobel Assembly at the Karolinska Institutet has today decided to award the 2024 Nobel Prize in Physiology or Medicine to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. This year’s Nobel Prize honours two scientists for their discovery of a fundamental principle governing how gene activity is regulated. The information stored within our chromosomes can be likened to an instruction manual for all cells in our body. Every cell contains the same chromosomes, so every cell contains exactly the same set of genes and exactly the same set of instructions. Yet, different cell types, such as muscle and nerve cells, have very distinct characteristics. How do these differences arise? The answer lies in gene regulation, which allows each cell to select only the relevant instructions. This ensures that only the correct set of genes is active in each cell type. This year’s medicine laureates Victor Ambros and Gary Ruvkun were interested in how different cell types develop. They discovered microRNA, a new class of tiny RNA molecules that play a crucial role in gene regulation. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. It is now known that the human genome codes for over one thousand microRNAs. Their surprising discovery revealed an entirely new dimension to gene regulation. MicroRNAs are proving to be fundamentally important for how organisms develop and function.
-
-
Today we announced completion of enrollment in the fourth cohort of our Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease. This is another step towards a possible treatment, and we are excited to be that much closer to potentially bringing this therapy to those living with #ADPKD. Learn more:?https://lnkd.in/ej78jaH4
-
-
We are excited to announce that Ed Lee, our VP of Translational Biology, will be presenting a poster on the discovery of our lead candidate, RGLS8429, currently being evaluated for the treatment of autosomal dominant polycystic kidney disease at the Oligonucleotide Therapeutics Society Annual Meeting in Montreal tomorrow. The poster, entitled “Deciphering and overcoming off-target AMPAR inhibition of anti-miR oligonucleotide RGLS4326,” will be available for viewing at 3:45 p.m. ET on October 8 – come check it out! #ADPKD #ots24 #oligomeeting
-
-
The Regulus team is looking forward to participating in the #WalkForPKD this Sunday. We’re proud to support the @pkdfoundation in their efforts to help improve the lives of those living with polycystic kidney disease!?#EndPKD https://walkforpkd.org/ ?
-
-
Did you know that there are approximately 12 million people living with autosomal dominant polycystic kidney disease worldwide? Today, on PKD Awareness Day, our team is taking the time to recognize those living with PKD, including #ADPKD, and their caregivers as we continue to advance our potential treatment, RGLS8429, through the clinic. ? #endPKD #PKDAwarenessDay
-
-
Catch our team at both the Wells Fargo Healthcare and H.C. Wainwright & Co., LLC Global Investors Conferences this month! If you’re attending, come listen to one of our presentations to learn more about our ongoing work in autosomal dominant polycystic kidney disease. ?#ADPKD?
-
-
Today we announced our second quarter financial results and recent updates. Read more: https://lnkd.in/ej8swmMn $RGLS
-